Submandibular Gland Stem Cell Transplantation (RESTART)
Autologous Transplantation of Adult Salivary Gland Stem Cells to Restore Submandibular Gland Function After Radiotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: R.J.H.M. Steenbakkers, MD, PhD
- Phone Number: +31 (0)503610034
- Email: r.steenbakkers@umcg.nl
Study Locations
-
-
-
Groningen, Netherlands
- Recruiting
- UMCG
-
Contact:
- R.J.H.M. Steenbakkers, MD,PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Squamous cell carcinoma (SCC) originating from the mucosa of the oral cavity;
- Primary resection of tumour including an electively or therapeutic ipsilateral neck dissection (at least levels Ib to III, including the submandibular gland).
- Postoperative radiotherapy or chemoradiation, including prophylactic or therapeutic irradiation of the contralateral side of the neck (where the remaining submandibular gland is), including at least levels Ib to IV), next to irradiation of the tumour bed and ipsilateral neck (current standard);
- Age ≥ 18 years;
- WHO performance 0-2;
- Written informed consent;
Exclusion Criteria:
- Primary (definitive) radiotherapy, with or without systemic treatment;
- Previous radiotherapy of the head and neck region (re-irradiation);
- Positive microbiological screening for Human Immunodeficiency Virus type 1 and 2, hepatitis B and C virus and Treponema pallidum.
- Presence of systemic disease known to affect salivary gland functioning (e.g., Sjögren's syndrome);
- Known allergy to mice and gentamicin
History within the past five years of malignancies other than:
- basal or squamous cell carcinoma of the skin
- in situ carcinoma of the cervix;
- Females who are pregnant or lactating at entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Transplantation
Submandibular Gland Stem Cell Transplantation
|
Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety: adverse events
Time Frame: Data for assessing safety will be recorded from day 1 to 365.
|
The number of adverse events (AE), serious adverse events (SAE) or suspected unexpected adverse reactions (SUSAR) after autologous salivary stem cell transplantation.
All possible adverse events will be scored according to the definitions of the Common Toxicity Criteria for Adverse Events version 4.0 (CTCAEv4.0).
|
Data for assessing safety will be recorded from day 1 to 365.
|
|
Feasibility: salivary flow rate
Time Frame: Data for assessing feasibility will be recorded 6 and 12 months after autologous stem cell transplantation to assess if salivary flow will be increased compared to salivary flow before transplantation.
|
The salivary flow rate of the remaining submandibular gland will be recorded.
|
Data for assessing feasibility will be recorded 6 and 12 months after autologous stem cell transplantation to assess if salivary flow will be increased compared to salivary flow before transplantation.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Salivary flow recovery
Time Frame: Saliva measurements at 6 and 12 months and then on a yearly basis until 5 years after postoperative (chemo)radiation
|
Unstimulated whole saliva, paraffin stimulated whole saliva and 5% citric acid stimulated parotid and submandibular/sublingual saliva measurements.
|
Saliva measurements at 6 and 12 months and then on a yearly basis until 5 years after postoperative (chemo)radiation
|
|
Impact of transplantation
Time Frame: Patient-rated outcome measures at 6 and 12 months and then on a yearly basis until 5 years after postoperative (chemo)radiation
|
Patient-rated outcome measures including various side effects related to the postoperative (chemo)radiation and Quality of Life (QoL) using internationally validated questionnaires.
|
Patient-rated outcome measures at 6 and 12 months and then on a yearly basis until 5 years after postoperative (chemo)radiation
|
|
Locoregional control
Time Frame: 5 years after postoperative (chemo)radiation
|
Locoregional control is defined as the number of patients with recurrent disease within or adjacent to the primary tumor site and regional lymph nodes after postoperative (chemo)radiation, assessed by pathology and/or oncologic imaging (CT, MRI or PET).
|
5 years after postoperative (chemo)radiation
|
|
Overall survival and disease-free survival
Time Frame: 5 years after postoperative (chemo)radiation
|
5 years after postoperative (chemo)radiation
|
|
|
Rate of water diffusion in remaining submandibular gland
Time Frame: 6 and 12 months after postoperative (chemo)radiation
|
The rate of water diffusion in remaining submandibular gland derived from DWI/DTI-MRI.
|
6 and 12 months after postoperative (chemo)radiation
|
|
Amount of PSMA
Time Frame: 6 and 12 months after autologous stem cell transplantation
|
The amount of prostate specific membrane antigen (PSMA) in the remaining submandibular gland derived from PET-CT
|
6 and 12 months after autologous stem cell transplantation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: R.J.H.M. Steenbakkers, MD, PhD, UMC Groningen
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RT2020-04
- NL75095.000.20 (Registry Identifier: CCMO register)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.